Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | PIK-93 | 1 | 72 | 0.032 | 4223.5 | 4331.0 | 1295.5 | -1.49 | 0.971 | 0.975 | 1.741 | HCC38 PIK93 0 1 72 |
| HCC38 | PIK-93 | 1 | 72 | 0.1 | 4112.5 | 4331.0 | 1295.5 | -1.0 | 0.941 | 0.950 | 1.741 | HCC38 PIK93 0 1 72 |
| HCC38 | PIK-93 | 1 | 72 | 0.32 | 3956.3 | 4331.0 | 1295.5 | -0.495 | 0.899 | 0.913 | 1.741 | HCC38 PIK93 0 1 72 |
| HCC38 | PIK-93 | 1 | 72 | 1.0 | 3760.8 | 4331.0 | 1295.5 | 0.0 | 0.844 | 0.868 | 1.741 | HCC38 PIK93 0 1 72 |
| HCC38 | PIK-93 | 1 | 72 | 3.2 | 2970.3 | 4331.0 | 1295.5 | 0.505 | 0.610 | 0.686 | 1.741 | HCC38 PIK93 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 0.001 | 3033.8 | 4278.0 | 1295.5 | -3.0 | 0.638 | 0.709 | 1.723 | HCC38 Rapamycin 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 0.0032 | 2831.8 | 4278.0 | 1295.5 | -2.49 | 0.574 | 0.662 | 1.723 | HCC38 Rapamycin 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 0.01 | 2870.0 | 4278.0 | 1295.5 | -2.0 | 0.586 | 0.671 | 1.723 | HCC38 Rapamycin 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 0.032 | 2839.8 | 4278.0 | 1295.5 | -1.49 | 0.577 | 0.664 | 1.723 | HCC38 Rapamycin 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 0.1 | 2853.3 | 4278.0 | 1295.5 | -1.0 | 0.581 | 0.667 | 1.723 | HCC38 Rapamycin 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 0.32 | 2746.0 | 4278.0 | 1295.5 | -0.495 | 0.546 | 0.642 | 1.723 | HCC38 Rapamycin 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 1.0 | 2759.8 | 4278.0 | 1295.5 | 0.0 | 0.551 | 0.645 | 1.723 | HCC38 Rapamycin 0 1 72 |
| HCC38 | Sirolimus | 1 | 72 | 3.2 | 2698.5 | 4278.0 | 1295.5 | 0.505 | 0.531 | 0.631 | 1.723 | HCC38 Rapamycin 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 0.001 | 4377.5 | 4281.3 | 1295.5 | -3.0 | 1.030 | 1.020 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 0.0032 | 4362.0 | 4281.3 | 1295.5 | -2.49 | 1.020 | 1.020 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 0.01 | 4351.0 | 4281.3 | 1295.5 | -2.0 | 1.020 | 1.020 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 0.032 | 4151.0 | 4281.3 | 1295.5 | -1.49 | 0.964 | 0.970 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 0.1 | 4375.3 | 4281.3 | 1295.5 | -1.0 | 1.030 | 1.020 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 0.32 | 4143.8 | 4281.3 | 1295.5 | -0.495 | 0.962 | 0.968 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 1.0 | 4074.5 | 4281.3 | 1295.5 | 0.0 | 0.943 | 0.952 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | TGX221 | 1 | 72 | 3.2 | 4056.3 | 4281.3 | 1295.5 | 0.505 | 0.938 | 0.947 | 1.724 | HCC38 TGX221 0 1 72 |
| HCC38 | Torin1 | 1 | 72 | 0.001 | 4193.8 | 4174.3 | 1295.5 | -3.0 | 1.010 | 1.000 | 1.688 | HCC38 Torin1 0 1 72 |
| HCC38 | Torin1 | 1 | 72 | 0.0032 | 3698.0 | 4174.3 | 1295.5 | -2.49 | 0.861 | 0.886 | 1.688 | HCC38 Torin1 0 1 72 |
| HCC38 | Torin1 | 1 | 72 | 0.01 | 3153.3 | 4174.3 | 1295.5 | -2.0 | 0.694 | 0.755 | 1.688 | HCC38 Torin1 0 1 72 |
| HCC38 | Torin1 | 1 | 72 | 0.032 | 2447.0 | 4174.3 | 1295.5 | -1.49 | 0.458 | 0.586 | 1.688 | HCC38 Torin1 0 1 72 |